Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02759107 · ClinicalTrials.gov registry record · Phase 1
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 142
- Enrollment target
NCT02759107 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 142 participants.
The verdict
NCT02759107, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 142 participants
- Enrollment target
Study Summary
The main purposes of this study are to determine: * The safety of tirzepatide and any side effects that might be associated with it. * How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it. * How tirzepatide affects the levels of blood sugar. This study includes 3 parts (A, B and C). Part A involves a single dose of tirzepatide taken as a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in duration, including screening. Parts B and C involve 4 doses of tirzepatide taken once weekly (over 4 weeks) as a SC injection just under the skin and is approximately 12-14 weeks in duration, including screening. Each participant will enroll in only one part. This study is for research purposes only, and is not intended to treat any medical condition.
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2017-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02759107
The ClinicalTrials.gov registry entry for NCT02759107 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02759107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02759107 about?
NCT02759107 is a clinical study titled "A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)". The main purposes of this study are to determine: * The safety of tirzepatide and any side effects that might be associated with it. * How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it. * How tirzepatide affects the levels of blood sugar. This study inc...
What is the current status of trial NCT02759107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 142 participants. The study started on 2016-05-11. Estimated completion is 2017-06-26.
What interventions are being tested in trial NCT02759107?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT02759107?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.